<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00386061</url>
  </required_header>
  <id_info>
    <org_study_id>EFC4733</org_study_id>
    <nct_id>NCT00386061</nct_id>
  </id_info>
  <brief_title>Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing Effect and Safety of SR141716 in Obese Patients With or Without Comorbidities (RIO-Europe)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The primary objective was to assess the effect of SR141716 on weight loss and weight
      maintenance over a period of one year when prescribed with a hypocaloric diet in obese
      patients with or without comorbidities.

      The main secondary objectives were to assess the effect of SR141716 on lipid parameters
      (HDL-C, TG), glucose tolerance status, the rate of patients with metabolic syndrome, waist
      circumference, glycemic parameters.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in body weight from baseline to 1 year.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>HDL-C and TG from baseline to 1 year; ·patients (%) with improvement of glucose tolerance, patients (%) with NCEP-ATPIII metabolic syndrome at 1 year.</measure>
  </secondary_outcome>
  <enrollment type="Actual">1507</enrollment>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rimonabant (SR141716)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  body mass index (BMI) e30 kg/m2 in patients with or without comorbidities, or BMI &gt;27
             kg/m2 in patients with treated or untreated hypertension and/or treated or untreated
             dyslipidemia.

          -  stable body weight (variation &lt;5 kg within 3 months prior to screening visit);

        Exclusion Criteria:

          -  History of very low-calorie diet within 6 months prior to screening visit; or history
             of surgical procedures for body weight loss (eg, stomach stapling, bypass);

          -  Presence of any clinically significant psychiatric , neurological or endocrine disease

          -  Presence of treated or untreated type 1 or type 2 diabetes);

          -  SBP &gt;165 mmHg and/or DBP &gt;105 mmHg on 2 consecutive visits from the screening to the
             inclusion visit;

          -  History of myocardial infarction or unstable angina pectoris within 6 months prior to
             screening visit; and history of stroke within 6 months prior to screening visit;

          -  Administration of anti-obesity drugs or other drugs for body weight reduction within 3
             months prior to screening visit;

        The investigator will evaluate whether there are other reasons why a patient may not
        participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bromma</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005 Apr 16-22;365(9468):1389-97. Erratum in: Lancet. 2005 Jul 30-Aug 5;366(9483):370.</citation>
    <PMID>15836887</PMID>
  </results_reference>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2006</study_first_submitted>
  <study_first_submitted_qc>October 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2006</study_first_posted>
  <last_update_submitted>April 17, 2009</last_update_submitted>
  <last_update_submitted_qc>April 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>risk factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rimonabant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

